Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2017-04-20 Annual Report
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
审计报告
Annual Report Classification · 95% confidence The document contains detailed financial statements including balance sheets, profit and loss statements, and notes for the years ending December 31, 2016 and 2015. The presence of comprehensive financial data such as assets, liabilities, equity, revenues, expenses, and net profit indicates this is a full annual financial report. The length of the document (15,000 characters) and the detailed financial tables confirm it is not a brief announcement or a certification. The document is consistent with the characteristics of an Annual Report (10-K equivalent) for a fiscal year.
2017-04-20 Chinese
关于为子公司提供贷款担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the board of directors of 马应龙药业集团股份有限公司 regarding the provision of loan guarantees to its subsidiaries. It details the guarantee amounts, the subsidiaries involved, their financial status, and the board's approval and opinions. The document is structured as a formal announcement with no financial statements or detailed financial analysis. It does not contain quarterly or annual financial results, audit opinions, or management discussion and analysis. The content focuses on a corporate action related to financing support (loan guarantees) for subsidiaries, which is a capital/financing update. The document length is 3405 characters, which is relatively short and typical for an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-04-20 Chinese
2017年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2017 年第一季度报告" which translates to "2017 First Quarter Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial data for the first quarter of 2017. The report is unaudited as stated in the text. The presence of comprehensive financial data for a quarter, including income, expenses, assets, liabilities, and cash flows, clearly identifies this as an interim or quarterly financial report. It is not an announcement or a brief summary but a full report with substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2017
2017-04-20 Chinese
2016年年度报告
Annual Report Classification · 100% confidence The document is titled "2016 年年度报告" which translates to "2016 Annual Report". It contains detailed financial data, including profit distribution plans, audited financial statements, management discussion and analysis, business overview, financial indicators, and risk disclosures. The presence of an audit report with an unqualified opinion is mentioned, but the document itself is comprehensive and includes the full annual report content rather than just the audit report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. The content includes detailed financial statements, business descriptions, management analysis, and other typical components of an annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2016
2017-04-20 Chinese
第九届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Mayinglong Pharmaceutical Group Co., Ltd. It includes approvals of the 2016 Supervisory Board Work Report, the 2016 Annual Report and summary, the 2016 Internal Control Evaluation Report, and the 2017 First Quarter Report. It also announces a change in the Supervisory Board membership. The document is a formal announcement of meeting resolutions and approvals rather than the full reports themselves. The length is short (1390 characters), and it serves as a notice of decisions made, including the approval of reports and a personnel change. Therefore, it is best classified as a Regulatory Filing (RNS) because it does not contain the full annual or quarterly reports but announces their approval and related supervisory board decisions.
2017-04-20 Chinese
2016年度审计委员会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2016 年度审计委员会工作报告' which translates to '2016 Annual Audit Committee Work Report'. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and discusses the audit committee's activities including oversight of external auditors, internal audit guidance, review of financial reports, and evaluation of internal controls for the year 2016. The content focuses on audit committee work and audit-related oversight rather than the full annual report or standalone audit opinion. It is a report from the audit committee to the board summarizing audit activities and findings for the year. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report, not the full Annual Report (10-K) or just an announcement. The document length is short (1126 characters), but it contains substantive audit committee content, not just a notice or certification. Therefore, the appropriate classification is AR with high confidence. FY 2016
2017-04-20 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.